Research progress on the treatment and prognosis of orbital lymphomas
10.3760/cma.j.cn115989-20200419-00272
- VernacularTitle:眼眶淋巴瘤的治疗及预后研究进展
- Author:
Mei SUN
1
;
Jianmin MA
Author Information
1. 首都医科大学附属北京同仁医院 北京同仁眼科中心 北京市眼科学与视觉科学重点实验室，北京 100730
- Keywords:
Orbital lymphoma;
Therapy;
Prognosis
- From:
Chinese Journal of Experimental Ophthalmology
2024;42(10):963-969
- CountryChina
- Language:Chinese
-
Abstract:
Orbital lymphomas (OLs) are the common orbital malignancies in adults.To date, many studies have reported the treatment of OLs, including radiotherapy, chemotherapy, immunotherapy, antibiotic therapy, surgical resection, or combination therapy.However, the selection of the best treatment is still a multidisciplinary task.Different treatment schemes were adopted for different subtypes and clinical stages of OLs.Radiotherapy is usually the first choice for the treatment of primary low-grade OLs, especially MALT lymphomas.Other non-MALT lymphomas can also be treated with radiotherapy, but the efficacy is not as good as MALT lymphomas.Chemotherapy is the most common choice for high-grade and other recurrent or refractory OLs.At present, rituximab combined with CHOP can significantly improve the prognosis of high-grade OLs.And antibiotics may be effective against a small portion of MALT lymphomas associated with Chlamydia psittaci infection.Also, studies have shown that histopathological subtypes and clinical stages are the most important factors affecting the prognosis of OLs.High-grade lymphomas have a poor prognosis, while the prognosis of low-grade lymphomas is better.Age, sex, the primary site of the disease and the use of various treatments are also related to prognostic outcomes of OLs.This article reviews the research on the treatment and prognostic factors of OLs at home and abroad to provide a reference for the formulation of clinical treatment plans and evaluate the prognosis.
